Yongrong Zhang Selected Research

trimethylaminocarboxyldihydroboran (TCDB)

1/2019	Structure of the full-length Clostridium difficile toxin B.
1/2019	Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
1/2018	Cysteine Protease-Mediated Autocleavage of Clostridium difficile Toxins Regulates Their Proinflammatory Activity.
12/2017	The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.
10/2016	Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.
7/2015	Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis.
2/2015	Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis.
2/2012	Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yongrong Zhang Research Topics

Disease

6	Infections 06/2022 - 02/2015
5	Clostridium Infections 10/2020 - 08/2012
4	Diarrhea 06/2022 - 07/2011
4	Colitis 01/2018 - 07/2011
3	Intestinal Diseases (Diseases, Intestinal) 10/2020 - 07/2015
3	Inflammation (Inflammations) 01/2018 - 08/2012
1	Pleural Effusion (Pleural Effusions) 06/2022
1	Dysbiosis 01/2022
1	Decompression Sickness (Bends) 01/2019
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2018
1	Ulcerative Colitis 12/2017
1	Crohn Disease (Crohn's Disease) 12/2017
1	Lung Neoplasms (Lung Cancer) 04/2015
1	Neoplasms (Cancer) 04/2015
1	Toxemia 02/2012
1	Paralysis (Palsy) 01/2012
1	Botulism 01/2012

Drug/Important Bio-Agent (IBA)

8	Anti-Bacterial Agents (Antibiotics)IBA 06/2022 - 07/2011
8	trimethylaminocarboxyldihydroboran (TCDB)IBA 01/2019 - 02/2012
3	CytokinesIBA 06/2022 - 02/2012
3	Virulence Factors (Pathogenicity Factors)IBA 01/2019 - 02/2015
2	AntitoxinsIBA 10/2020 - 02/2015
1	Monoclonal AntibodiesIBA 10/2020
1	Coloring Agents (Dyes)IBA 01/2019
1	SaltsIBA 01/2018
1	Dextran SulfateIBA 01/2018
1	Clostridium difficile tcdA proteinIBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 12/2017
1	Single-Domain AntibodiesIBA 10/2016
1	EnzymesIBA 07/2015
1	GlucosyltransferasesIBA 07/2015
1	ResveratrolIBA 04/2015
1	PolyphenolsIBA 04/2015
1	bezlotoxumabIBA 02/2015
1	AntibodiesIBA 02/2015
1	actoxumabIBA 02/2015
1	Immunotoxins (Immunotoxin)IBA 08/2012
1	VaccinesIBA 08/2012
1	Clostridium difficile toxB proteinIBA 01/2012
1	Botulinum Toxins (Botulinum Toxin)IBA 01/2012
1	Peptide Hydrolases (Proteases)FDA Link 01/2012

Therapy/Procedure

2	Therapeutics 06/2022 - 01/2018
1	Immunotherapy 10/2020
1	Parenteral Infusions 10/2020
1	Laparotomy 12/2017